Multiple Myeloma Coverage from Every Angle

European Commission Approves Split-Dose of Daratumumab in Multiple Myeloma

By: Sarah Jackson
Posted: Wednesday, January 30, 2019

It has been announced that the European Commission has granted authorization to provide health-care professionals with the option to split the first infusion of daratumumab for patients with multiple myeloma. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Daratumumab is a first-in-class biologic targeting CD38 regardless of disease stage and is believed to induce tumor cell death through multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis, as well as through apoptosis.

The decision was based on data from the phase Ib EQUULEUS study ( identifier NCT01998971), which demonstrated that the pharmacokinetics concentrations of daratumumab were comparable regardless of whether the first dose was administered as a split infusion or a single first infusion in patients with multiple myeloma. The safety profile of daratumumab was comparable when administered initially as a split or a single dose.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.